Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) | RFA EB 21 001

Opportunity Information: Apply for RFA EB 21 001

Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional) is an NIH funding opportunity focused on cutting health disparities by supporting the creation and translation of practical medical technologies that can be used in real-world settings. NIH uses the term "health disparities" to mean measurable differences in disease rates and outcomes, including incidence, prevalence, morbidity, mortality, and overall burden, across specific groups. The program is explicitly aimed at populations that experience disproportionate health burdens, including racial and ethnic minority groups (such as African Americans, American Indians, Alaska Natives, Asian Americans, Hispanic/Latino Americans, Native Hawaiians, and other U.S. Pacific Islanders, including subpopulations within these groups), people who are socioeconomically disadvantaged, sexual and gender minority communities, and medically underserved groups in both rural and urban areas.

The heart of the opportunity is technology development that can realistically move the needle on disparities tied to diseases and conditions that matter for public health. NIH is looking for projects that go beyond a good idea on paper and instead push toward translation, meaning a clear pathway toward actual deployment and use. The announcement highlights a wide range of eligible technology areas, including medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, and mathematical, computational, or modeling approaches. The common thread is that the technology should address healthcare needs that are specific to, or more acute within, populations experiencing disparities, rather than simply being a general-purpose innovation with a vague connection to equity.

A key requirement is that the proposed technology must be appropriate for the target community and setting. NIH emphasizes four baseline characteristics: the technology should be effective, affordable, culturally acceptable, and easily accessible to the people who need it. In practice, that means applicants should be thinking about usability in low-resource clinics, constraints in rural environments, cultural and linguistic fit, cost and reimbursement realities, and adoption barriers like transportation, digital access, and trust in healthcare systems. Technologies that are technically advanced but too expensive, too complex to maintain, or not designed around the lived realities of the intended users would be a poor fit for the stated goals of the program.

Another central feature is collaboration. Responsive applications are expected to include a formal partnership with a healthcare organization or public health agency that serves one or more disparity populations. This signals that NIH wants the work grounded in real service environments, with input from organizations that understand the community and can support testing, implementation planning, workflow integration, and eventual dissemination. In many cases, this kind of partner can also strengthen recruitment plans, provide access to clinical or public health data, and help ensure the technology is designed with the right constraints and priorities from the start.

The award mechanism is an R01, and clinical trials are optional under this announcement, meaning projects may include a clinical trial if it is appropriate to the stage and goals of development, but a trial is not required. The opportunity is listed as discretionary funding and falls under NIH health-related activity categories, with CFDA numbers 93.286 and 93.307. The posted award ceiling is $500,000, indicating an upper bound on the amount expected per award under this announcement.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations other than small businesses; small businesses; and other eligible entities. The announcement also specifically calls out a range of mission-aligned institutions and organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, regional organizations, certain tribal governments (other than federally recognized), and U.S. territories or possessions.

Restrictions on foreign involvement are clear. While the text mentions non-domestic entities in a way that can be confusing, the bottom line stated in the opportunity is that non-U.S. (foreign) institutions are not eligible to apply, non-domestic components of U.S. organizations are not eligible to apply, and foreign components as defined by NIH policy are not allowed. In other words, applicants should plan for the project to be fully U.S.-based in both applicant organization status and project components.

Administrative details in the source information include the Funding Opportunity Number RFA EB 21 001, with the agency listed as the National Institutes of Health. The original closing date provided is 2025-05-02. Overall, this opportunity is best suited to teams that can pair strong engineering or technology development capabilities with credible community- or clinic-based partners, and that can demonstrate a realistic route to a solution that is not only innovative, but also affordable, acceptable, and accessible for populations that have historically been left behind by many health technology advances.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technology Development to Reduce Health Disparities (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.286, 93.307.
• This funding opportunity was created on 2021-12-10.
• Applicants must submit their applications by 2025-05-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA EB 21 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: